# Citius Oncology, Inc. (CTOR)

> Source: Nexqual · https://nexqual.com/CTOR · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Citius Oncology, Inc. (CTOR), nexqual.com/CTOR" · informational, not investment advice.

**Price:** USD 0.75 (-1.43% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.76 · day 0.75–0.77 · 52w 0.49–2.25 · market cap $78.9M · NCM

## Key facts
- Analysts: Strong Buy (mean 1.00 on a 1–5 scale) (1 analysts), mean target USD 4 (range 4–4).
- Total return with dividends: 1Y -58.3% vs S&P 500 +18.1%; 5Y -92.6% vs S&P 500 +85.1%.

## Analysts
Consensus Strong Buy (mean 1.00 on a 1–5 scale), 1 analysts; mean target USD 4 (low 4, high 4).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2022-12-05) |
|---|---|---|
| Total return | -58.3% | -92.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -58.5% | -49.1% |
| Volatility (annualized) | 91.3% | 190.2% |
| Max drawdown | -72.5% (Oct 2025→Mar 2026) | -98.7% (Aug 2024→Mar 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.31 +7.13% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/CTOR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt